Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma-Reference-Cited by-同舟云学术

Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma

Published:2017-02 Issue:2 Volume:23 Page:262-268
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Sivaraj Dharshan^ORCID,Green Michael M.,Li Zhiguo,Sung Anthony D.,Sarantopoulos Stefanie,Kang Yubin,Long Gwynn D.,Horwitz Mitchell E.,Lopez Richard D.,Sullivan Keith M.,Rizzieri David A.,Chao Nelson J.,Gasparetto Cristina

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference31 articles.

1. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma;Child;N Engl J Med,2003

2. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial;Palumbo;Blood,2004

3. Autologous transplantation and maintenance therapy in multiple myeloma;Palumbo;NEJM,2014

4. Clinical course of patients with relapsed multiple myeloma;Kumar;Mayo Clin Proc,2004

5. Autologous hematopoietic stem-cell transplantation for multiple myeloma;Harousseau;NEJM,2009

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Introductory Chapter: Update on Multiple Myeloma;Recent Updates on Multiple Myeloma;2023-03-15

2. Outpatient Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma;Recent Updates on Multiple Myeloma;2023-03-15

3. An Update on Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma;Recent Updates on Multiple Myeloma;2023-03-15

4. Outcome of Outpatient Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma and Relapsed and Refractory Hodgkin Lymphoma. The Experience of King Fahad Specialist Hospital in Dammam, Saudi Arabia;Journal of Stem Cell Therapy and Transplantation;2023-03-08

5. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial;The Lancet Oncology;2023-02